SavedAdd your journal

Journals / Eurasian Journal of Medical Investigation / 2022 / Cilt: 6 - Sayı: 1

Does Orlistat Affect Levothyroxine Bioavailability?

Bünyamin AYDIN
Pages
22–27
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

When BMI of group 1 were compared at baseline and third month, it was found to be statistically lower (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Orlistat is used in the treatment of obesity while hypothyroidism is treated with levothyroxine.
📊
Key Findings & Data:Patients with a body mass index (BMI) > 40 and receiving levothyroxine replacement therapy were included in the study.
💡
Conclusion & Impact:When BMI of group 1 were compared at baseline and third month, it was found to be statistically lower (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Orlistat is used in the treatment of obesity while hypothyroidism is treated with levothyroxine. In this study, the effect of orlistat treatment on thyroid stimulating hormone (TSH) was investigated. Methods: The files of the patients who were followed up with the diagnosis of obesity and hypothyroidism were evaluated retrospectively. Patients with a body mass index (BMI) > 40 and receiving levothyroxine replacement therapy were included in the study. Group 1 consisted of 37 patients who received orlistat and levothyroxine while group 2 consisted of patients who received levothyroxine without orlistat. BMI and TSH values of patients were compared at baseline and at third month. Results: Despite group 1 having mild increase in TSH at third month compared to baseline, no statistically significant difference was observed (p:0.328). No differences were observed between TSH values of group 2 at baseline and third month (p: 0.380). When BMI of group 1 were compared at baseline and third month, it was found to be statistically lower (p

🔖

Cite This Article

AYDIN, B. (2022). Does Orlistat Affect Levothyroxine Bioavailability?. Eurasian Journal of Medical Investigation, Cilt: 6 - Sayı: 1, 22–27. https://ajindex.com/articles/508535

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. WHO. Obesity: preventing and managing the global epidemic. Technical report series No. 894, Geneva: WHO; 2000
  2. Hollander PA. Orlistat. Drugs 2001;61:2120–21
  3. Lee M, Lauren BN, Zhan T, Choi J, Klebanoff M, Abu Dayyeh B, et al. The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity. Obes Sci Pract 2019;6:162–70
  4. Cahill A, Lean MEJ: Review article: malnutrition and maltreatment: a comment on orlistat for the treatment of obesity. Aliment Pharmacol Ther 1999;13:997–1002
  5. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet 2017;390:1550–62
  6. Akagunduz B, Akcakaya M. Evaluation of the correlation of urea, creatine, and uric acid levels with TSH in patients with newly diagnosed overt and subclinic hypothyroidism. EJMI 2021;5:317–21
  7. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 2008;31:53–65
  8. Sweetman S. Martindale: the complete drug reference. London: Pharmaceutical Press. Available at:http://www.medicinescomplete.com/mc/martindale/current/9000-a5-z.html. Accessed Jan 2, 2014
  9. Madhava K, Hartley A. Hypothyroidism in thyroid carcinoma follow-up: orlistat may inhibit the absorption of thyroxine. Clin Oncol (R Coll Radiol) 2005;17:492
  10. Chiffoleau A, De Mallmann V, Lambert J, Bodin X. Interaction between orlistat and levothyroxine: a first French case report. Fundam Clin Pharmacol 2010;24:1–1
  11. Pai MP, Paloucek FP. The origin of the “ideal” body weight equations. Ann Pharmacother 2000;34:1066–9
  12. McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002;10:642–50
  13. Benvenga S. L-T4 Therapy in the Presence of Pharmacological Interferents. Front Endocrinol (Lausanne) 2020;11:607446
  14. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:167–72
  15. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000;160:1321–6